Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval
2017 ◽
Vol 95
(2)
◽
pp. 261-290
◽
HUSEYIN NACI
◽
OLIVIER J. WOUTERS
◽
RADHIKA GUPTA
◽
JOHN P.A. IOANNIDIS
2020 ◽
Vol 3
(7)
◽
pp. e209498
◽
Andrea MacGregor
◽
Audrey D. Zhang
◽
Joshua D. Wallach
◽
Joseph S. Ross
◽
Matthew Herder
2018 ◽
Vol 178
(11)
◽
pp. 1451
◽
Thomas J. Moore
◽
Hanzhe Zhang
◽
Gerard Anderson
◽
G. Caleb Alexander
2021 ◽
Vol 4
(11)
◽
pp. e2133601
Joshua D. Wallach
◽
Reshma Ramachandran
◽
Till Bruckner
◽
Joseph S. Ross
2020 ◽
Vol 3
(4)
◽
pp. e203284
◽
Audrey D. Zhang
◽
Jeremy Puthumana
◽
Nicholas S. Downing
◽
Nilay D. Shah
◽
Harlan M. Krumholz
◽
...
2021 ◽
Vol 4
(11)
◽
pp. e2133667
Joshua D. Wallach
◽
Audrey D. Zhang
◽
Joshua J. Skydel
◽
Victoria L. Bartlett
◽
Sanket S. Dhruva
◽
...
Mahnum Shahzad
◽
Huseyin Naci
◽
Anita K. Wagner
2020 ◽
Vol 180
(12)
◽
pp. 1701
James L. Johnston
◽
Sanket S. Dhruva
◽
Joseph S. Ross
◽
Vinay K. Rathi
2002 ◽
Vol 7
(5)
◽
pp. 390-392
◽
Martin H. Cohen
◽
Marie L. Moses
◽
Richard Pazdur
2017 ◽
Vol 69
(4)
◽
pp. 479-496
◽
Nathan P. Coussens
◽
John C. Braisted
◽
Tyler Peryea
◽
G. Sitta Sittampalam
◽
Anton Simeonov
◽
...
2017 ◽
Vol 318
(7)
◽
pp. 626
◽
Huseyin Naci
◽
Katelyn R. Smalley
◽
Aaron S. Kesselheim